Department of Radiology, Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Liver Transpl. 2024 Feb 1;30(2):160-169. doi: 10.1097/LVT.0000000000000257. Epub 2023 Sep 13.
This study aimed to evaluate the effectiveness of different treatments for hepatic artery thrombosis (HAT) and hepatic artery stenosis (HAS) after pediatric liver transplantation. We systematically reviewed studies published since 2000 that investigated the management of HAT and/or HAS after pediatric liver transplantation. Studies with a minimum of 5 patients in one of the treatment methods were included. The primary outcomes were technical success rate and graft and patient survival. The secondary outcomes were hepatic artery patency, complications, and incidence of HAT and HAS. Of 3570 studies, we included 19 studies with 328 patients. The incidence was 6.2% for HAT and 4.1% for HAS. Patients with an early HAT treated with surgical revascularization had a median graft survival of 45.7% (interquartile range, 30.7%-60%) and a patient survival of 61.3% (interquartile range, 58.7%-66.9%) compared with the other treatments (conservative, endovascular revascularization, or retransplantation). As for HAS, endovascular and surgical revascularization groups had a patient survival of 85.7% and 100% (interquartile range, 85%-100%), respectively. Despite various treatment methods, HAT after pediatric liver transplantation remains a significant issue that has profound effects on the patient and graft survival. Current evidence is insufficient to determine the most effective treatment for preventing graft failure.
本研究旨在评估不同治疗方法对小儿肝移植后肝动脉血栓形成(HAT)和肝动脉狭窄(HAS)的疗效。我们系统地回顾了自 2000 年以来发表的研究,这些研究调查了小儿肝移植后 HAT 和/或 HAS 的治疗方法。纳入了至少有 5 例患者接受一种治疗方法的研究。主要结局为技术成功率、移植物和患者存活率。次要结局为肝动脉通畅性、并发症、HAT 和 HAS 的发生率。在 3570 项研究中,我们纳入了 19 项研究共 328 例患者。HAT 的发生率为 6.2%,HAS 的发生率为 4.1%。早期 HAT 患者接受手术再血管化治疗的中位移植物存活率为 45.7%(四分位间距,30.7%-60%),患者存活率为 61.3%(四分位间距,58.7%-66.9%),与其他治疗方法(保守治疗、血管内再血管化或再次肝移植)相比。对于 HAS,血管内和手术再血管化组的患者存活率分别为 85.7%和 100%(四分位间距,85%-100%)。尽管有多种治疗方法,但小儿肝移植后 HAT 仍然是一个严重的问题,对患者和移植物存活率有深远的影响。目前的证据不足以确定预防移植物失功的最有效治疗方法。